High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.

Luke J PepponeAmber S KlecknerChunkit FungJ Edward PuzasJennifer E ReschkeEva CulakovaJulia InglisCharles S KamenJonathan W FriedbergMichelle JanelsinsKaren MustianCharles E HecklerSupriya Mohile

Published in: Cancer (2024)

HDVD supplementation significantly reduced hip and femoral neck BMD loss, especially for patients with low baseline serum 25-hydroxyvitamin D levels, although demonstrating safety and feasibility in prostate cancer patients on ADT.

Keyphrases

prostate cancer
bone loss
high dose
radical prostatectomy
low dose
stem cell transplantation
stem cells